ADIA Nutrition Inc. Requests SIC Code Update to 2836 (Biological Products) with SEC and OTC Markets

Winter Park, Florida–(Newsfile Corp. – November 17, 2025) – ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced it has filed with the SEC to update its Standard Industrial Classification (SIC) code from 2834 (Pharmaceutical Preparations) to 2836 (Biological Products, Except Diagnostic) and with OTC Markets to update from 6719 (Holding Companies, N.E.C.) to 2836 (Biological Products, Except Diagnostic), accurately reflecting its core business of manufacturing and distributing proprietary biologics.

Email to SEC

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/274544_sic_filing_corrections.jpg

This dual request aligns ADIA’s classification with its real operations:

• Adia Labs LLC sells FDA-registered 361 HCT/Ps (AdiaVita, AdiaLink) sold nationwide to physicians.
• Adia Med clinics, owned by ADIA, perform specialty regenerative treatments including stem cell therapy, PRP, and advanced biologics.

“We are not a supplement, pharma, or holding company,” said Larry Powalisz, CEO of ADIA Nutrition. “We are a biotech company scaling biological products through labs and clinics. Updating to SIC 2836 across both SEC and OTC Markets gives investors and partners full clarity on our true growth model.”

The updates will take effect upon ADIA’s next filings. ADIA’s 2025 momentum, 200%+ Q3 revenue growth, OTCQB uplisting progress, and expanding clinic network, solidifies its biotech identity.

Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia’s regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia’s continued mission to expand access to advanced stem cell solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274544